iShares MSCI India ETF vs Novavax Inc — how do they compare? iShares MSCI India ETF trades at $49.94, while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: iShares MSCI India ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| INDA | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $11.19 |
52-Week Low | $45.42 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% with a bullish technical signal supported by moving averages. The ETF tracks India's market, which grew 7.8% in Q1 2026 (CNBC, June 5, 2026), but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Key support and resistance cluster around $50.
Outlook remains mixed: India's strong economic growth offers long-term potential, but near-term risks include Middle East disruptions affecting exports (Reuters, August 4, 2026) and AI-driven pressure on IT firms. Institutional sentiment is cautious amid foreign capital rotation.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →